Siemens Healthineers Molecular Imaging has entered into a research collaboration with leading healthcare institution Massachusetts General Hospital (MGH) to support the use of theranostics. The ability to diagnose disease with one radiopharmaceutical and treat it with a similar therapeutic agent, theranostics has been used to treat certain types of cancer, including thyroid cancer, prostate cancer, and neuroendocrine cancer. Typically, molecular imaging is used in theranostics to identify the extent of disease and monitor treatment response.
Siemens Healthineers and MGH will establish a Therapy Command Center to support the use of theranostics across MGH and its affiliated centers in Massachusetts, Maine, and New Hampshire. The Therapy Command Center will help MGH collect theranostics-related data, provide real-time monitoring capabilities, and support physicians in determining the most appropriate path forward for each patient.
Also Read: Siemens Healthineers Acquires Advanced Accelerator Applications Molecular Imaging
“This research collaboration, which is based on a relationship between Siemens Healthineers and Massachusetts General Hospital that spans more than 20 years, will enable innovations along the patient’s clinical pathway, provide precision diagnoses, and deliver highly effective forms of customized therapy,” said James Williams, PhD, head of Siemens Healthineers Molecular Imaging.
“The Therapy Command Center helps provide a framework that will enable the integration of a wide variety of patient imaging and laboratory data, combined with population-based data for enhanced individual patient outcomes,” said Umar Mahmood, MD, PhD, chief of nuclear medicine and molecular imaging, Massachusetts General Hospital. “This collaboration will help expand theranostics across the region, advancing personalized medicine through precision diagnoses and tailored therapies. Our focus on examining radiation’s impact on tumors and normal tissues will further improve treatment protocols and outcomes while decreasing toxicity to normal organs.”
As part of this collaboration, Siemens Healthineers and MGH researchers will use Biograph Vision Quadra and Biograph Trinion positron emission tomography/computed tomography (PET/CT) scanners to examine the effects of radiation on molecular and biological processes, as well as the toxicity levels in the cancer cells and healthy tissues of patients who receive radiopharmaceutical therapy. Understanding these effects is crucial to advancing the concept of personalized medicine.
